← Human Trials & Peer-Reviewed Studies
Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
Plain-language guide to PMID 38750410 (2024): randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 38750410
- Journal
- BMC cancer
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Hauner D et al. (8 authors)
- DOI
- 10.1186/s12885-024-12341-3
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
The aim of the present analysis was to assess the prevalence of dietary supplement (DS) intake among women before and after a breast cancer diagnosis.
Multivariate logistic regression models were fitted to examine differences in DS intake between the two intervention groups.
The groups were then pooled to examine differences in DS use between the prediagnostic and postdiagnostic period.
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, women only.
Participants in the SUCCESS C lifestyle intervention study, a randomized controlled trial in women with newly diagnosed intermediate- to high-risk breast cancer, completed two questionnaires on dietary supplement intake 24 months (QS1) and 48 months (QS2) after beginning the lifestyle intervention.
How the Study Was Run
The design is described as randomized.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
The study was registered on 12.17.2008 under the EU Clinical Trials Register https://www.clinicaltrialsregister.eu/, trial registration number: 2008-005453-38.
The questionnaires collected data on DS intake during the 5-year period prediagnosis (QS1) and in the period postdiagnosis (QS2).
What Was Measured
PubMed files the paper under topics including Dietary Supplements, Breast Neoplasms, Surveys and Questionnaires and Life Style.
The authors tagged it with the keywords Breast cancer, Dietary supplement use, Excess intake, Inadequate intake and Micronutrients.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement).
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (BMC cancer), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.